Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study

Yu Zhang, Shuo Cao, Nan Niu, Huilian Shan, Jinqi Xue, Guanglei Chen, Yongqing Xu, Jianqiao Yin, Chao Liu, Lisha Sun, Xiaofan Jiang, Meiyue Tang, Qianshi Xu, Mingxuan Jia, Xu Zhang, Zhenyong Zhang, Qingfu Zhang, Jianfei Wang, Ailin Li, Yongliang Yang, Caigang Liu
doi: https://doi.org/10.1101/2024.08.31.24312890

Article usage

Article usage: September 2024 to April 2025

AbstractFullPdf
Sep 20241092429
Oct 202421123
Nov 20243009
Dec 202425219
Jan 20254749
Feb 20252523846
Mar 2025522918
Apr 202554914
Back to top
Posted September 01, 2024.
Download PDF
Email
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
Yu Zhang, Shuo Cao, Nan Niu, Huilian Shan, Jinqi Xue, Guanglei Chen, Yongqing Xu, Jianqiao Yin, Chao Liu, Lisha Sun, Xiaofan Jiang, Meiyue Tang, Qianshi Xu, Mingxuan Jia, Xu Zhang, Zhenyong Zhang, Qingfu Zhang, Jianfei Wang, Ailin Li, Yongliang Yang, Caigang Liu
medRxiv 2024.08.31.24312890; doi: https://doi.org/10.1101/2024.08.31.24312890
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area